EANO 2019

EPTEMBER 19 - 22, 2019 14TH Meeting & Educational Day LYON, FRANCE

T



www.eano.eu

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

Centre de Congrès Lyon, France




TABLE OF CONTENTS



GENERAL

Welcoming Address2	
Committees – Board – Organisation	
Accreditation & Future Meetings4	

SCIENTIFIC PROGRAMME

Programme at a Glance	
Detailed Scientific Programme	

Educational Days

Thursday, September 19

EANO – EORTC Educational Day
Clinical Track
Basic/Translational Track
Educational Day for Nurses and AHPs10
EANO Meeting
Thursday, September 19
Friday, September 20
Saturday, September 21
Sunday, September 22
Side Meetings

SCIENTIFIC INFORMATION

Oral Presentations .									.2	26	
Poster Presentations		 • •							.2	8	

CORPORATE SYMPOSIA

Corporate Lunch Symposium 1	32
Corporate Lunch Workshop 1	32
Corporate Lunch Symposium 2	33
Corporate Symposium 3	33

INFORMATION

Networking Events
General Information
Registration
Sponsors
Exhibitors

WELCOMING ADDRESS

DEAR COLLEAGUES, DEAR FRIENDS,





We are delighted to welcome you in Lyon at the $14^{\mbox{\tiny th}}$ EANO annual meeting.

As you will see, the 2019 EANO programme has a lot to offer from various backgrounds. Whether you are a clinician, a scientist, a nurse specialized in neuro-oncology or new in the field, you will find presentations that will increase your knowledge. The speakers come from many countries, institutions and specialties and will give you a plethora of information and experiences that will make the EANO 2019 a successful meeting.

The programme and the education day cover the hotest topics in Neuro-Oncology with focus on the new development in brain tumors biomarkers, treatments, clinical trials and novel developments in immune-oncology. A special focus on paraneoplastic neurological syndromes is also planned. Outstanding science will be presented in oral talks selected from the submitted abstracts with also two afternoon poster sessions.

Lyon is at the crossroads of Europe and is the second largest metropolitan area in France, ideally located, close to the Beaujolais, the Vallée du Rhône vineyards and the Alps. A major part of the city centre has been listed by UNESCO as a world heritage site, which is not surprising as Lyon can still show the remains of 20 centuries of History. But above all, the city is very famous for its gastronomy: from its 14 starred restaurants and to the typical and charming bistros called "Bouchons".

Enjoy your stay to visit the city that has unique museums that have no equal elsewhere in the world, such as the Lumière Institute on the invention of cinematography, the Fabric Museum tracing two thousand years of the history of textile and silk weaving, the museum of Confluences opening in December 2014 with its highly surprising architecture, the National Opera, one of the twenty most prestigious ballets in the world, and the Célestins Theatre that offer an ambitious programme all year.

Lyon is vibrant all year round thanks to a number of events it hosts attracting millions of visitors every year. Lyon is truly the ideal place to experience the best of France!

Welcome to Lyon and the EANO meeting 2019!

All the best,

Jérôme Honnorat President EANO 2019 Meeting Martin Van den Bent President EANO

COMMITTEES – BOARD – ORGANISATION

EANO Scientific Committee

Congress President Jérôme Honnorat, Lyon (FR)

Chair

Michael Platten, Mannheim (DE)

Members

Florien Willemijn Boele, Leeds (UK) Elizabeth Cohen-Jonathan Moyal, Toulouse (FR) Jaime Gállego Pérez de Larraya, Pamplona (ES) Oliver Hanemann, Plymouth (UK) Christian Mawrin, Magdeburg (DE) Emilie Le Rhun, Lille (FR) Federico Pessina, Milan (IT) Stefan Pfister, Heidelberg (DE) Manuel Valiente, Madrid (ES)

EANO Office

Wiener Medizinische Akademie GmbH Ms. Magdalena Mara Alser Strasse 4 1090 Vienna, Austria T: +43 1 405 13 83 31 F: +43 1 405 13 83 931 E: office@eano.eu www.eano.eu



EANO Executive Board

President: Martin van den Bent, Rotterdam (NL) Past President: Wolfgang Wick, Heidelberg (DE) Treasurer: Matthias Preusser, Vienna (AT)

Asgeir Jakola, Gothenburg (SE) Simone Niclou, Luxembourg (LU) Karin Piil, Copenhagen (DK) Patrick Roth, Zurich (CH) Roberta Rudà, Turin (IT) Felix Sahm, Heidelberg (DE) Marilena Theodorou, Nicosia (CY) Jérôme Honnorat, Lyon (FR) Anthony Chalmers, Glasgow (UK) Anna Berghoff, Vienna (AT) Michael Platten, Mannheim (DE) Riccardo Soffietti, Turin (IT) Michael Weller, Zurich (CH)

EANO 2019 Conference Organisation

Scientific Management, Exhibition and Sponsorhip, General organisation and logistics Wiener Medizinische Akademie GmbH Ms. Anja Rosenkranz Ms. Kristina Theuerer-Libova Alser Strasse 4 1090 Vienna, Austria T: +43 1 405 13 83 11 F: +43 1 407 82 74 E: eano-meetings@eano.eu



Venue of EANO 2019

Centre de Congrès - CITÉ 50 Quai Charles de Gaulle 69463 Lyon Cedex 06 France T: +33 4 72 82 26 26 www.ccc-lyon.com



ACCREDITATION & FUTURE MEETINGS

CME CREDITS

The 14th Meeting of the European Association of Neuro-Oncology, Lyon, France, 19/09/2019- 22/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME[®]) with 24 European CME credits (ECMEC[®]s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME[®] credits to an equivalent number of *AMA PRA Category 1 Credits™*. Information on the process to convert EACCME[®] credit to AMA credit can be found at www.ama-assn.org/education/ earn-credit-participation-international-activities.



Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME[®] for ECMEC[®]s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 9 and 23 of UEMS 2016.20.

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day. Cf. Chapter X of UEMS 2016.20.

CME CERTIFICATE/CONFIRMATION OF ATTENDANCE

Confirmations of attendance and payment will be issued electronically via email after the conference to all participants. Participants interested in obtaining CME credits need to get their name badges scanned **daily** at the Registration Desk and will be able to download their CME Certificate after completion of the post-congress survey. Please note that if you miss to scan your badge you will not receive the credits accredited for that day.

FUTURE CONFERENCES

EANO 2020 September 10-13, 2020 | Scottish Event Campus, Glasgow (UNITED KINGDOM)

EANO 2021 September 23-26, 2021 | De Doelen, Rotterdam (NETHERLANDS)

EANO 2022 September 15-18, 2022 | Hofburg Vienna, Vienna (AUSTRIA)

More information will be available online at www.eano.eu closer to the conferences.

SCIENTIFIC PROGRAMME



Programme at a Glance
Detailed Scientific Programme
Educational Days Thursday, September 19
EANO – EORTC Educational Day Clinical Track. Basic/Translational Track. 9 Educational Day for Nurses and AHPs
EANO Meeting .11 Thursday, September 19. .11 Friday, September 20. .12 Saturday, September 21. .19 Sunday, September 22. .23
Side Meetings

#`& **#**`& **#**`&

PROGRAMME AT A GLANCE

	Thurs	day, Septemb	er 19	Friday, September 20								
Room	Bellecour	Gratte-Ciel	Tête d'Or 1	Amphithéâtre	Bellecour	Gratte-Ciel	Tête d'Or 1	Tête d'Or 2	Tête d'Or Lounge			
Level	-1	2	1	0	-1	2	1	1	1			
		Educational Day	/			EANO Meeti	ng					
	Clinical track	Basic/ Translational track	Nurses and Allied Health Professionals									
08:00 - 08:15		Hansiational track	ricalul Floressionals									
08:15 - 08:30		Welcome address		Meet the Expert	Meet the Expert Session 2	Meet the Expert			•••••••••••••••••••••••••••••••••••••••			
08:30 - 08:45	Welcome address		Welcome address & Introduction to French clinical practice	Session 1 Brain Metastases	Nursing and AHP Perspective	Session 3 Local Therapies						
08:45 - 09:00		Neuro-oncology			reispective							
09:00 - 09:15	Diagnostic	breakthroughs	Symptom									
09:15 - 09:30 09:30 - 09:45	developments	in 2018	management	09:00 - 10:30	09:00 - 10:30	09:00 - 10:30 Oral Session 3			••••••			
09:45 - 10:00				Oral Session 1 Liquid Biomarker	Oral Session 2 Spinal Tumors	Value of patient-						
10:00 - 10:15	Coffee break	Coffee break	Coffee break			reported outcomes						
10:15 - 10:30												
10:30 - 10:45 10:45 - 11:00	Current therapies				10:30 - 11:05 Coffee break							
11:00 - 11:15	for brain tumor patients			11:10-11:20								
11:15 - 11:30		New Developments	Surgery and	Opening and Presidential Addr.					••••••			
11:30 - 11:45		in molecular technologies	cognitive assessment	11:20 - 12:50								
11:45 - 12:00		teennonogies		Plenary								
12:00 - 12:15 12:15 - 12:30	Clinical trials in neuro-oncology			Session 1 Low Grade Glioma					•••••••••••••••••••••••••••••••••••••••			
12:15 - 12:50												
12:45 - 13:00		Lunch break	Lunch break		13:05 - 14:20 Corporate Lunch Symposium For details see	12:50 - 14:20 Lunch break		12:50	- 13:20			
13:00 - 13:15							13:05 - 14:20	Lunch	break			
13:15 - 13:30 13:30 - 13:45	Lunch break			12:50 - 14:20 Lunch break			Corporate Lunch	13:20 - 14:20 Workshop 2:	13:20 - 14:20 Workshop 1:			
13:45 - 14:00							Workshop For details see	Handling high throughput	Mentoring session on "How to plan			
14:00 - 14:15		New developments	On-going		page 31		page 31	data	your career in Neuro-Oncology"			
14:15 - 14:30	Update on rare	in IDH mutant gliomas	PhD-projects		1							
14:30 - 14:45 14:45 - 15:00	CNS tumors											
15:00 - 15:15		Coffee have b	Coffee breeds	14:25 - 15:55	14:25 - 15:55	14:25 - 15:55						
15:15 - 15:30	Coffee break	Coffee break	Coffee break	Oral Session 4 Early clinical trials	Oral Session 5 DIPG	Oral Session 6 Metabolic Pathways						
15:30 - 15:45 15:45 - 16:00												
16:00 - 16:15	Epilepsy and	Epilepsy and Immunotherapy:										
16:15 - 16:30	cognition across tumor types and	where next	planning and management			16:05 - 17:35			•••••••••••••••••••••••••••••••••••••••			
16:30 - 16:45	treatments			16:05 - 17:35 Oral Session 7	16:05 - 17:35 Oral Session 8	Oral Session 9 Omics in						
16:45 - 17:00 17:00 - 17:15				QoL	Meningeoma	neuro-oncology						
17:15 - 17:30									••••••			
17:30 - 17:45	17:15 - 18:15	17:15 - 18:15 Women										
17:45 - 18:00	Meet the editor	in neuro-oncology										
18:00 - 18:15 18:15 - 18:30				Poster Vie	17:45 - 19:15 wing 1 - with wine a	and cheese						
18:30 - 18:45					Poster Topics 1-12							
18:45 - 19:00					For details see page 28	8						
19:00 - 19:15												
19:15 - 19:30 19:30 - 19:45												
19:45 - 20:00												
20:00 - 20:15		Networking Event										
20:15 - 20:30		For details see page 36			oungsters Networki For details see page 3							
20:30 - 20:45 20:45 - 21:00					r or uctains see page 3.							
21:00 - 21:15												
21:15 - 21:30									••••••			

For exact times please see Detailed Scientific Programme. The titles of presentations given by our invited speakers are in bold font. During the Educational Day, all speakers are invited.



Scientific Programme

PROGRAMME AT A GLANCE

	Saturday	Sunday, September 22				
Amphithéâtre	Bellecour	Gratte-Ciel	Tête d'Or 2	Tête d'Or Lounge	Amphithéâtre	Room
0	-1	2	1	1	0	Level
	EAI	NO Meeting			EANO Meeting	
	08:00 - 09:00					08:00 - 08:
08:00 - 09:00 Wake Up Session 1	Wake Up Session 2 EANM-EANO	08:00 - 09:00 Wake Up Session 3				08:15 - 08:
PCNSL	Session - PET	Microenvironment			08:30 - 09:30	08:30 - 08:
	Imaging				EANO Youngsters Session	08:45 - 09:
	09:10 - 10:30			••••••		09:15 - 09:
09:10 - 10:30	Pro & Con	09:10 - 10:30 Pro & Con				09:30 - 09:
loint EAN-EANO Symposium on	Session 1 Controversies	Session 2 Controversies in			09:30 - 10:30 EANO General Assembly	09:45 - 10
Veuroimmunology	in Imaging and Radiotherapy	Molecular Markers			LANG General Assembly	10:00 - 10:
	10:30 - 11:00			•••••	10:30 - 11:00	10:10 - 10:
	Coffee break				Coffee break	10:45 - 11:
					11:00 - 11:30 Progress in neuro-oncology 2019:	11:00 - 11:
11:00 - 12:30	11:00 - 12:30	11:00 - 12:30			strategy of the BTG	11:15 - 11:
Oral Session 10	Oral Session 11	Oral Session 12			11:30- 12:30	11:30 - 11:
Highlights from clinical abstracts	EANO / SNO Session	Highlights from preclinical abstracts			Plenary	11:45 - 12
					Session 3 Hot Topics	12:00 - 12:
			10.20	12.00	10.20 10.45	12:15 - 12: 12:30 - 12:
				- 13:00 1 break	12:30 - 12:45 Closing Remarks	12:45 - 13:
12:30 - 14:00	12:45 - 14:00 Corporate Lunch	12:30 - 14:00	12.00 14.00	12.00 14.00		13:00 - 13:
Lunch break Symposium	Lunch break	Workshop 3:	13:00 - 14:00 Workshop 4:		13:15 - 13:	
	For details see page 31		Preclinical Models	Clinical trial design		13:30 - 13:
				8		13:45 - 14:
						14:00 - 14: 14:15 - 14:
14:05 - 15:35 Plenary						14:30 - 14:
Session 2						14:45 - 15:
Immunotherapy						15:00 - 15:
						15:15 - 15
						15:30 - 15: 15:45 - 16:
						16:00 - 16
Poster Viev	15:45 - 17:15 wing 2 - with wine a	and cheese				16:15 - 16
1	Poster Topics 13-14	1				16:30 - 16:
	For details see page 28	>				16:45 - 17:
	1715 1000					17:00 - 17:
	17:15 - 18:00 Corporate					17:15 - 17:
	Symposium For details see page 31					17:30 - 17: 17:45 - 18:
	, or details see page 31	I				18:00 - 18:
				••••••		18:15 – 18:
						18:30 - 18:
						18:45 - 19:
						19:00 - 19: 19:15 - 19:
				••••••		19:15 - 19: 19:30 - 19:
	EANO Evening	7		••••••		19:45 - 20:
	For details see page 33					20:00 - 20:
						20:15 - 20:
						20:30 - 20:
						20:45 - 21:
						21:00 - 21:

For exact times please see Detailed Scientific Programme. The titles of presentations given by our invited speakers are in bold font. During the Educational Day, all speakers are invited.

EANO – EORTC EDUCATIONAL DAY: Clinical Track

Thursday, September 19

Room: Bellecour

08:30 – 08:40	Welcome Address Martin van den Bent (Rotterdam, NL) on behalf of EANO and EORTC
08:40 - 09:55	Diagnostic developments Chairs: Dominique Figarella Branger (Marseille, FR), Marta Nowosielski (Innsbruck, AT)
08:40 - 09:05 09:05 - 09:30	Clinical applications of the new WHO classification; <i>Pieter Wesseling (Utrecht, NL)</i> Methylation profiling for clinicians; <i>David Capper (Berlin, DE)</i>
09:30 - 09:55	Pitfalls in the radiological assessment of brain tumor therapies; <i>Marta Nowosielski (Innsbruck, AT)</i>
09:55 – 10:15	Coffee break
10:15 – 11:25	Current therapies for brain tumor patients; Chairs: Anthony Chalmers (Glasgow, UK), Emilie Le Rhun (Lille, FR)
10:15 - 10:40 10:40 - 11:05 11:05 - 11:25	Radiotherapy and alkylating chemotherapy; <i>Anthony Chalmers (Glasgow, UK)</i> Targeted therapy and immunotherapy; <i>Martin van den Bent (Rotterdam, NL)</i> Assessing new treatments in Europe; <i>Vassilis Golfinopoulos (Brussels, BE)</i>
11:25 – 13:00	Clinical trials in neuro-oncology Chairs: Martin van den Bent (Rotterdam, NL), Wolfgang Wick (Heidelberg, DE)
11:25 - 11:50 11:50 - 12:15 12:15 - 12:40 12:40 - 13:00	Surgical trials; <i>Manfred Westphal (Hamburg, DE)</i> Gliomas; <i>Michael Weller (Zurich, CH)</i> CNS metastasis; <i>Emilie Le Rhun (Lille, FR)</i> Strategies and pitfalls of clinical trial design; <i>Martin van den Bent (Rotterdam, NL)</i>
13:00 - 14:00	Lunch break
14:00 – 15:20	Update on rare CNS tumors <i>Chairs:</i> Asgeir Jakola (Gothenburg, SE), Irene Slavc (Vienna, AT)
14:00 - 14:20	Pilocytic astrocytomas, histone-mutated gliomas, and pleomorphic xanthoastrocytomas <i>Riccardo Soffietti (Turin, IT)</i>
14:20 - 14:40	Neuronal and neuronal-glial tumors; Asgeir Jakola (Gothenburg, SE)
14:40 – 15:00 15:00 – 15:20	Neurofibromatosis type 1 and 2; <i>Irene Slavc (Vienna, AT)</i> Trials in rare brain tumors; <i>Peter Hau (Regenburg, DE)</i>
15:20 - 15:40	Coffee Break
15:40 – 17:00	Epilepsy and cognition across tumor types and treatments <i>Chairs: Joachim Steinbach (Frankfurt, DE), Roberta Rudà (Turin, IT)</i>
15:40 - 16:00	Epilepsy in glial tumors; Roberta Rudà (Turin, IT)
16:00 - 16:20	Epilepsy in non-glial tumors; Joachim Steinbach (Frankfurt, DE)
16:20 - 16:20 16:20 - 16:40 16:40 - 17:00	Neurocognitive functioning in primary brain tumors; <i>Martin Klein (Amsterdam, NL)</i> Cognition in Brain Tumors in children; <i>Didier Frappaz (Lyon, FR)</i>



7 T

#\ #\ #

8

EANO – EORTC EDUCATIONAL DAY: Basic/Translational Track

Thursday, September 19

Room: Gratte-Ciel

08:20 – 08:30	Welcome address Simone Niclou (Luxembourg, LU)
08:30 - 10:00	Neuro-oncology breakthroughs in 2018 Chairs: Pim French (EORTC, Rotterdam, NL) & Simone Niclou (EANO, Luxembourg, LU)
08:30 – 09:00	Highlights of 2018 (basic science) <i>Monika Hegi (Lausanne, CH)</i>
09:00 – 09:30	Highlights of 2018 (clinical trials) Wolfgang Wick (Heidelberg, DE)
09:30 - 10:00	Update on the molecular classification of adult gliomas <i>Francois Ducray (Lyon, FR)</i>
10:00 - 10:30	Coffee break
10:30 – 12:30	New developments in molecular technologies Chairs: Pim French (EORTC, Rotterdam, NL) & Simone Niclou (EANO, Luxembourg, LU)
10:30 - 11:00	New developments in paediatric neuro-oncology Marta Alonso (Pamplona, ES)
11:00 - 11:30	Measuring oncogenic signaling pathway activation for precision medicine (OncoSignal) Anja van de Stolpe (Eindhoven/NL)
11:30 – 12:00	Rethinking EGFR as target Pim French (Rotterdam, NL)
12:00 - 12:30	The target landscape of clinical kinase drugs: what is the future of kinase inhibitors? <i>Bernhard Küster (Munich, DE</i>)
12:30 – 13:30	Lunch break
13:30 – 15:00	New developments in IDH mutant gliomas Chairs: Martine Lamfers (Rotterdam, NL), Houtan Noushmehr (Detroit, US)
13:30 - 14:00	Significance of methylator phenotypes Houtan Noushmehr (Detroit, US)
14:00 - 14:30	Oncogenic IDH mutations: a clinical perspective Marc Sanson (Paris, FR)
14:30 - 15:00	Metabolic aspects of IDH mutant gliomas Daniel Tennant (Birmingham, UK)
15:00 - 15:30	Coffee break
15:30 – 17:00	Immunotherapy: where next Chairs: Martine Lamfers (Rotterdam, NL), Houtan Noushmehr (Detroit, US)
15:30 - 16:00	The basics of immunotherapy Michael Platten (Mannheim, DE)
16:00 - 16:30	Microglia and macrophages in brain malignancies Lisa Sevenich (Frankfurt, DE)
16:30 – 17:00	Priming the immune response for checkpoint blockade Susan Short (Leeds, UK)



EDUCATIONAL DAY FOR NURSES AND AHPS

Thursday, September 19

Room: Tête d'Or 1

NURSE – EDUCATIONAL DAY

10

08:30 – 08:35	Welcome Image: Welcome Image: Welcome Karin Piil (Copenhagen, DK) Image: Welcome Image: Welcome
08:35 – 08:50	Introduction to French clinical practice Alexandra Redon (Lyon, FR)
08:50 – 10:00	Symptom management Chairs: Ingela Oberg (Cambridge, UK), Karin Piil (Copenhagen, DK)
08:50 - 09:20	Guide to management of major symptoms in patients with malignant glioma Terri Armstrong (Bethesda, US)
09:20 - 09:40	Interventions for symptom management and improving quality of life – what is the state of the evidence? <i>Florien Boele (Leeds, UK)</i>
09:40 - 10:00	From newly diagnosed to long-term survivorship; Karin Piil (Copenhagen, DK)
10:00 - 10:30	Coffee break
10:30 – 12:30	Surgery and cognitive assessment
	Chairs: Karin Piil (Copenhagen, DK), Aleksandar Stanimirovic (Beograd, RS)
10:30 - 11:15	Advances in neurosurgery for brain tumours; Asgeir Jakola (Gothenburg, SE)
11:15 – 11:45	Threshold for awake glioma surgery: Choosing the right candidate Aleksandar Stanimirović (Beograd, RS)
11:45 – 12:30	Consequences of neurological deficits after tumor surgery Martin Klein (Amsterdam, NL)
12:30 – 13:30	Lunch break
13:30 - 15:00	On-going PhD-projects
	Chairs: Petra Hoogendoorn (Amsterdam, NL), Lena Rosenlund (Stockholm, SE)
13:30 - 13:50	Shared decision making for patients with recurrent malignant brain tumour <i>Helle Soerensen Von Essen (Odense, DK</i>)
13:50 - 14:10	Supportive care needs of TYA childhood brain tumour survivors and their caregivers: A mixed method study; <i>Emma Nicklin (Leeds, UK)</i>
14:10 - 14:30	Patient reported outcomes for person-centered care; Lena Rosenlund (Stockholm, SE)
14:30 – 14:50 14:50 – 15:00	Development and testing of an App; Goings-on; <i>Petra Hoogendoorn (Amsterdam, NL)</i> Discussions
15:00 – 15:30	Coffee break
15:30 - 17:00	Advance care planning and management Chairs: Ingela Oberg (Cambridge, UK), Karin Piil (Copenhagen, DK)
15:30 - 16:00	Management of adult glioma in nursing practice - Editing a book Ingela Oberg (Cambridge, UK)
16:00 - 16:30	Difficult conversations around a life limiting diagnosis: how to discuss what matters most <i>Helen Bulbeck (Isle of Wight, UK)</i>
16:30 - 16:45	Closing remarks; Karin Piil (Copenhagen, DK), Alexandra Redon (Lyon, FR)



EANO MEETING

ste ste ste

Thursday, September 19

- 17:15 18:15 Meet the Editor **Room: Bellecour** Chair: Wolfgang Wick (Heidelberg, DE) 17:15 - 17:35 Neuro-Oncology Ken Aldape (Toronto, CA) 17:35 - 17:55Neuro-Oncology Advances Gelareh Zadeh (Toronto, CA) 17:55 - 18:15 **Neuro-Oncology Practice** Susan Chang (San Francisco, US) 17:15 - 18:15 EANO Women in Neuro-oncology **Room: Grette-Ciel** Chairs: Linda Dirven (Rotterdam, NL), Simone Niclou (Luxembourg, LU) 17:15 - 17:20Introduction Martin van den Bent (Rotterdam, NL) 17:20 - 17:32 What is happening in the US? Susan Chang (San Francisco, US) Results of the EANO gender issue committee survey 17:32 - 17:47 Emilie Le Rhun (Lille, FR)

17:47 - 18:00

19:00 – 21:30 EANO Networking Evening Lyon City Hall - Hôtel de Ville

Discussion

Spend a nice evening with your colleagues while enjoying finger food and drinks. *Please note that advance registration is mandatory in order to receive a ticket! Limited attendance, individual arrival. See page 36 for further details.*



EANO MEETING

Friday, September 20

08:00 – 09:00	Meet the Expert 1: Brain metastases Room: Amphithéâtre
	Chairs: Anna Berghoff (Vienna, AT), Riccardo Soffietti (Turin, IT)
08:00 - 08:20	Immune control of brain metastases Mihaela Lorger (Leeds, UK)
08:20 - 08:40	Clinical trials in brain metastases Anna Berghoff (Vienna, AT)
08:40 - 09:00	Microenvironment in brain metastases Manuel Valiente (Madrid, ES)
08:00 - 09:00	Meet the expert 2: Nursing and AHP perspective Room: Bellecour
	Chairs: Florien Boele (Leeds, UK), Karin Piil (Copenhagen, DK)
08:00 - 08:20	Multidisciplinary teamwork in the management of adult glioma Ingela Oberg (Cambridge, UK)
08:20 - 08:40	Monitoring, understanding and managing cognitive problems in cancer patients without CNS disease: putting knowledge into practice <i>Sanne Schagen (Amsterdam, NL)</i>
08:40 - 09:00	Mental capacity framework Heather Ayles (Cambridge, UK)
08:00 – 09:00	Meet the Expert 3: Local therapies Room: Gratte-Ciel
	Chairs: Clemens Dirven (Rotterdam, NL), Jaime Gállego Pérez de Larraya (Pamplona, ES)
08:00 - 08:20	Virotherapy Annick Desjardins (Duke, US)
08:20 - 08:40	CAR T cells Hideho Okada (San Francisco, US)
08:40 - 09:00	Disrupting the BBB Ahmed Idbaih (Paris, FR)
09:00 - 10:30	Oral Session 1: Liquid biomarker Room: Amphithéâtre
	Chairs: Oliver Hanemann (Plymouth, UK), Joachim Steinbach (Frankfurt, DE)
09:00 - 09:22	Tumor-educated platelets <i>Tom Würdinger (Amsterdam, NL)</i>
09:22 – 09:28	Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients <i>Maximilian Mair (Vienna, AT)</i>
09:28 – 09:34	Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma Jian-Guo Zhou (Zunyi City, CN)
09:34 - 09:40	Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis <i>Guido Ahle (Colmar, FR)</i>
09:40 - 09:46	Liquid biopsy of the CSF in a series of GBM patients: preliminary results. Francesco Bruno (Turin, IT)
09:46 -09:52	Detection of glioma and prognostic subtypes by non-invasive circulating cell-free DNA methylation markers <i>Houtan Noushmehr (Detroit, US)</i>

09:52 –09:58	Peripheral blood immune profiles at first recurrence of IDH wild type glioblastoma after standard chemoradiotherapy predict overall survival: secondary analyses of the phase II DIRECTOR trial <i>Hans-Georg Wirsching (Zurich, CH)</i>
09:58– 10:04	Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls. <i>Emeline Tabouret (Marseille, FR)</i>
10:04- 10:26	Cell-free tumor DNA Joan Seoane (Barcelona, ES)
09:00 - 10:30	Oral Session 2: Spinal tumors Room: Bellecour
00.00.00.00	Chairs: Federico Pessina (Milan, IT), Gelareh Zadeh, (Toronto, CA)
09:00 – 09:26	Surgical approaches to intramedullary tumors Jörg Tonn (Munich, DE)
09:26 – 09:52	Novel concepts of radiotherapy of spinal tumors Giuseppe Minniti (Rome, IT)
09:52 – 09:59	Incidence patterns for primary spinal cord ependymomas in adults: a Surveillance, Epidemiology, and End Results study <i>Weitao Man (Beijing, CN)</i>
09:59 - 10:06	Chemotherapy for spinal gliomas in adults Dorothee Gramatzki (Zurich, CH)
10:06 - 10:13	Relevance of Neurofibromatosistype 1 and schwannomotosis in extramedullary spine tumors <i>Marica Eoli (Milan, IT)</i>
10:13 - 10:20	Using FineSA MRI for early detection of Spinal Metastases Ayako Niina (Cardiff, UK)
10:20 - 10:30	Discussion time 37°
09:00 – 10:30	Oral Session 3: Value of patient-reported outcomes Room: Gratte-Ciel
09:00 – 10:30	
09:00 - 10:30 09:00 - 09:22	Room: Gratte-Ciel
	Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology
09:00 – 09:22	Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need?
09:00 – 09:22 09:22 – 09:44	Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need? Linda Dirven (Leiden, NL) Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients
09:00 – 09:22 09:22 – 09:44 09:44 – 09:50	 Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need? Linda Dirven (Leiden, NL) Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients Pim van der Meer (Leiden, NL) Relevant topics for brain tumor patients in the Distress Thermometer, first results of the HEAT study.
09:00 – 09:22 09:22 – 09:44 09:44 – 09:50 09:50 – 09:56	 Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need? Linda Dirven (Leiden, NL) Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients Pim van der Meer (Leiden, NL) Relevant topics for brain tumor patients in the Distress Thermometer, first results of the HEAT study. Mirjam Renovanz (Tuebingen, DE) Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III
09:00 - 09:22 09:22 - 09:44 09:44 - 09:50 09:50 - 09:56 09:56 - 10:02	 Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need? Linda Dirven (Leiden, NL) Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients Pim van der Meer (Leiden, NL) Relevant topics for brain tumor patients in the Distress Thermometer, first results of the HEAT study. Mirjam Renovanz (Tuebingen, DE) Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III Quirien Oort (Amsterdam, NL) Karnofsky and WHO performance scores of brain tumour patients may limit inclusion in protocols though they depend on clinician status.
09:00 - 09:22 09:22 - 09:44 09:44 - 09:50 09:50 - 09:56 09:56 - 10:02 10:02 - 10:08	 Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need? Linda Dirven (Leiden, NL) Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients Pim van der Meer (Leiden, NL) Relevant topics for brain tumor patients in the Distress Thermometer, first results of the HEAT study. Mirjam Renovanz (Tuebingen, DE) Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III Quirien Oort (Amsterdam, NL) Karnofsky and WHO performance scores of brain tumour patients may limit inclusion in protocols though they depend on clinician status. Didier Frappaz (Lyon, FR) Prescription medications in glioma patients and the prevalence of depression, anxiety and subjective cognitive impairment
09:00 - 09:22 09:22 - 09:44 09:44 - 09:50 09:50 - 09:56 09:56 - 10:02 10:02 - 10:08 10:08 - 10:14	 Room: Gratte-Ciel Chairs: Florien Boele (Leeds, UK); Martin Taphoorn (Leiden, NL) Clinical implementation of patient-reported outcomes in neuro-oncology Mirjam Renovanz (Tübingen, DE) Neurocognitive outcome parameters – how much do we need? Linda Dirven (Leiden, NL) Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients Pim van der Meer (Leiden, NL) Relevant topics for brain tumor patients in the Distress Thermometer, first results of the HEAT study. Mirjam Renovanz (Tuebingen, DE) Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours: phase I-III Quirien Oort (Amsterdam, NL) Karnofsky and WHO performance scores of brain tumour patients may limit inclusion in protocols though they depend on clinician status. Didier Frappaz (Lyon, FR) Prescription medications in glioma patients and the prevalence of depression, anxiety and subjective cognitive impairment Pim van der Meer (Leiden, NL) Prediagnostic symptoms and signs of adult glioma: the patients' view

#\ #

11:10 – 11:20	Meeting opening and presidential address Room: Amphithéâtre Chairs: Jérôme Honnorat (Lyon, FR), Martin van den Bent (Rotterdam, NL)
11:20 – 12:50	Plenary Session 1: Low grade glioma Room: Amphithéâtre
	Chairs: François Ducray (Paris, FR), Sevin Turcan (Heidelberg, DE)
11:20 - 11:50	Single cell resolution of low grade glioma Itay Tirosh (Rehovot, IL)
11:50 - 12:20	Challenges in the treatment of low grade glioma Jean-Yves Delattre (Paris, FR)
12:20 - 12:30	CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas Dominique Figarella-Branger (Marseille, FR)
12:30 - 12:40	Multiparametric assessment of factors influencing 2 HG accumulation in diffuse brain gliomas <i>Lucia Nichelli (Paris, FR)</i>
12:40 - 12:45	Discussion led by: Martin van den Bent (Rotterdam, NL)
12:45 - 12:50	Q&A
12:50 – 14:20	Lunch break
	Corporate Lunch Symposium and Corporate Lunch Workshop For details see page 31
13:20 - 14:20	Workshop 1: Mentoring session on "How to plan your career in Neuro-Oncology" Room: Tête d'Or Lounge
	Pre-registration required, no fee. One-hour face-to-face discussion with 6 mentors. Please come to the registration desk to see if seats are still available. In case you booked this workshop, there are small initials on your badge.
	Table 1: How to plan your career in Neuro-Oncology: Clinical Neuro-Oncology Mentor: Riccardo Soffietti (Turin, IT)
	Table 2: How to plan your career in Neuro-Oncology: Clinical Neuro-Oncology Mentor: Matthias Preusser (Vienna, AT)
	Table 3: How to plan your career in Neuro-Oncology: Laboratory Science Mentor: Manuel Valiente (Madrid, ES)
	Table 4: How to plan your career in Neuro-Oncology: Laboratory ScienceMentor: Monika Hegi (Lausanne, CH)
	Table 5: How to plan your career in Neuro-Oncology: Neurosurgery Mentor: Lorenzo Bello (Milan, IT)
	Table 6: How to plan your career in Neuro-Oncology: Neurosurgery Mentor: Miriam Ratliff (Mannheim, DE)
13:20 - 14:20	Workshop 2: Handling high throughput data Room: Tête d'Or 2
	Chairs: Olivier Ayrault (Paris, FR), Carina Thomé (Heidelberg, DE)
	Pre-registration required, no fee. Please come to the registration desk to see if seats are still available. In case you booked this workshop, there is a mark with the workshop number on your badge.
13:20 - 13:25	Itay Tirosh (Rehovot, IL)
13:25 – 13:30	Sevin Turcan (Heidelberg, DE)
13:30 - 13:35	Olivier Ayrault (Paris, FR)
13:35 - 14:15	Discussion
14:15 - 14:20	Summary



14:25 – 15:55	Oral Session 4: Early clinical trials Room: Amphithéâtre
	Chairs: Michael Weller (Zurich, CH), Emeline Tabouret (Marseille, FR)
14:25 - 14:44	How to test targeted therapies in neuro-oncology Tracy Batchelor (Boston, US)
14:44 - 15:03	Trial design challenges in pediatric neuro-oncology Sabine Müller (San Francisco, US)
15:03 - 15:22	NCI-CONNECT Mark Gilbert (Bethesda, US)
15:22 – 15:30	MEVITEM: A European, randomized, open-label, Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic Hedgehog (SHH) pathway. <i>Didier Frappaz (Lyon, FR)</i>
15:30 - 15:38	Phase 0 trial of Ceritinib in brain metastasis and recurrent glioblastoma Nader Sanai (Phoenix, US)
15:38 – 15:46	Feasibility and benefit of Molecular Profiling to Guide Enrollment of Patients with Recurrent Gliomas in Early Phase Trials <i>Capucine Baldini (Villejuif, FR)</i>
15:46 – 15:54	Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma : Results of the phase I part of the phase I/II STERIMGLI trial. <i>Elizabeth Cohen-Jonathan Moyal (Tourlouse, FR)</i>
14:25 – 15:55	Oral Session 5: DIPG Room: Bellecour
14:25 – 15:55	
14:25 - 15:55 14:25 - 14:50	Room: Bellecour
	Room: Bellecour Chairs: Marta Alonso (Pamplona, ES), Chris Jones (London, UK) Heterogeneity in DIPG
14:25 – 14:50	Room: Bellecour Chairs: Marta Alonso (Pamplona, ES), Chris Jones (London, UK) Heterogeneity in DIPG Javad Nazarian (Zurich, CH) Overcoming resistance in DIPG
14:25 – 14:50 14:50 – 15:15	Room: Bellecour Chairs: Marta Alonso (Pamplona, ES), Chris Jones (London, UK) Heterogeneity in DIPG Javad Nazarian (Zurich, CH) Overcoming resistance in DIPG Chris Jones (London, UK) Phase I clinical trial with oncolytic virus DNX-2401 for DIPGs
14:25 – 14:50 14:50 – 15:15 15:15 – 15:23	Room: BellecourChairs: Marta Alonso (Pamplona, ES), Chris Jones (London, UK)Heterogeneity in DIPGJavad Nazarian (Zurich, CH)Overcoming resistance in DIPGChris Jones (London, UK)Phase I clinical trial with oncolytic virus DNX-2401 for DIPGsMarta Alonso (Pamplona, ES)Distinct immune and molecular profile of pediatric and adult diffuse midline gliomas
14:25 - 14:50 14:50 - 15:15 15:15 - 15:23 15:23 - 15:31	Room: BellecourChairs: Marta Alonso (Pamplona, ES), Chris Jones (London, UK)Heterogeneity in DIPGJavad Nazarian (Zurich, CH)Overcoming resistance in DIPGChris Jones (London, UK)Phase I clinical trial with oncolytic virus DNX-2401 for DIPGsMarta Alonso (Pamplona, ES)Distinct immune and molecular profile of pediatric andadult diffuse midline gliomasKavneet Kaur (New Delhi, IN)Quantitative signaling pathway analysis of Diffuse Intrinsic Pontine Gliomaidentifies two subtypes, respectively high TGFβ/MAPK-AP1 and high PI3K/HHpathway activity, which are potentially clinically actionable

14:25 – 15:55	Oral Session 6: Metabolic pathways Room: Gratte-Ciel	
	Chairs: Anthony Chalmers (Glasgow, UK), Simone Niclou (Luxembourg, LU)	
14:25 - 14:45	Mitochondria and energy metabolism in glioblastoma Heiko Wurdak (Leeds, UK)	
14:45 – 15:05	Inhibiting immunosuppressive IDO1 in patients with malignant glioma – a moving target that changes with treatment, cell of origin, and aging Lijie Zhai (Chicago, US)	
15:05 - 15:14	Targeting Purine Metabolism to Overcome Therapeutic Resistance in Glioblastoma Atique Ahmed (Chicago, US)	
15:14 - 15:23	Loss of CYP46A1 directs altered cholesterol homeostasis and opens therapeutic opportunities for glioblastoma <i>Mingzhi Han (Bergen, NO)</i>	
15:23 – 15:32	The complex role of lactate dehydrogenases in glioblastoma development Thomas Daubon (Pessac, FR)	
15:32 – 15:41	The hypoxia-induced glioma derived exosome miRNA-199a-3p promotes glioma cells proliferation and increased ischemic injury of the para-tumor neurons by inhibiting mTOR pathway – A pivotal ischemic mechanism in the proliferation and growth of glioma <i>Jian-Lan Zhao (Shanghai, CN)</i>	
15:41 – 15:50	ERGO2: A prospective randomized trial of a 9-day schedule of calorically restricted ketogenic diet and fasting or standard diet in addition to re-irradiation for malignant glioma <i>Martin Voss (Frankfurt, DE)</i>	
16:05 – 17:35	Oral Session 7: QoL Room: Amphithéâtre	
	Chairs: Linda Dirven (Leiden, NL), Andrea Pace (Rome, IT)	
16:05 – 16:25	Challenges in survivorship in ependymoma Terri Armstrong (Bethesda, US)	
16:25 – 16:45	How to standardize assessment and analysis of QoL data Martin Taphoorn (Leiden, NL)	
16:45 – 16:51	Impact of the addition of Rituximab to standard therapy with high dose methotrexate on health-related quality of life in primary central nervous system lymphoma patients <i>Matthijs van der Meulen (Rotterdam, NL)</i> <i>This presenter will receive the award for the best abstract in "Patient-related outcomes" during the session.</i>	
16:51 – 16:57	Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making <i>Marijke Coomans (Leiden, NL)</i>	
16:57 – 17:03	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients <i>Giuseppe Lombardi (Padova, IT)</i>	
17:03 – 17:09	Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM) <i>Marijke Coomans (Leiden, NL)</i>	
17:09 – 17:15	Healthcare utilization, medication use, and productivity loss in glioma patients with depressive symptoms and their family caregivers <i>Florien Boele (Leeds, UK)</i>	
17:15 – 17:21	Socioeconomic burden and associations with quality of life in meningioma patients <i>Hans-Georg Wirsching (Zurich, CH)</i>	
17:21 – 17:27	Educational program for caregivers of patients with brain tumors: AGAPE Elodie Vauléon (Rennes, FR)	

16:05 – 17:35	Oral Session 8: Meningeoma Room: Bellecour
16:05 – 16:25	Chairs: Felix Sahm (Heidelberg, DE), Jörg Tonn (Munich, DE) Molecular classifications of meningioma – how much detail do we need? Felix Sahm (Heidelberg, DE)
16:25 – 16:45	Clinical Trial Designs in Meningioma Matthias Preusser (Vienna, AT)
16:45 - 16:51	A phase 0/2 clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients Nader Sanai (Phoenix, US)
16:51 - 16:57	Risk stratification in chordoid meningioma depends on mutation status and epithelial differentiation <i>Adriana Olar (Charleston, US)</i>
16:57 – 17:03	Gamma knife radiosurgery for large meningiomas: 10 years of experience <i>Khaled Abdel Karim (Cairo, EG)</i>
17:03 – 17:09	Impact of brain invasion assessment on outcome in intracranial grade II meningiomas <i>Thiébaud Picart (Bron, FR)</i>
17:09 – 17:15	How to assess meningioma therapy activity: The CEVOREM independent central review experience <i>Thomas Graillon (Marseille, FR)</i>
17:15 - 17:21	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02 <i>Emilie Le Rhun (Lille, FR)</i>
17:21 – 17:27	Targeting Pi3k-Akt-mTOR and MAPKinase pathways in aggressive meningiomas: in vitro study. Gregoire Mondielli (Marseille, FR)
17:27 – 17:33	Modified chromatin histone marks at noncoding elements are associated with aggressive meningioma subtype <i>Houtan Noushmehr (Detroit, US)</i>
16:05 – 17:35	Oral Session 9: Omics in neuro-oncology Room: Gratte-Ciel
	Chairs: Lucy Stead (Leeds, UK), David Capper (Berlin, DE)
16:05 - 16:25	Uncovering heterogeneity of glioblastoma by epigenomics Johanna Klughammer (Vienna, AT)
16:25 – 16:45	Value of phosphoproteomics for classification and target discovery Olivier Ayrault (Paris, FR)
16:45 – 16:51	Clinical significance of hypermutation in gliomas Mehdi Touat (Boston, US)
16:51 - 16:57	Radiomics analysis of lower-grade gliomas, a POLA Network study. Nadia Younan (Paris, FR) This presenter will receive the award for the best abstract in "Clinical sciences" during the session.
16:57 – 17:03	Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusion <i>Alberto Picca (Pavia, IT)</i>
17:03 – 17:09	The added value of radiomics to a clinical prognostic model in patients with low-grade glioma <i>Michiel van Riel (Rotterdam, NL)</i>
17:09 – 17:15	Evidence that adult glioblastoma adapts to standard therapy though chromatin remodeling Lucy Stead (Leeds, UK)
17:15 – 17:21	Diagnosis of pseudoprogression using FET PET radiomics Philipp Lohmann (Juelich, DE)
17:21 – 17:27	Telomere length, TERTp mutation and ALT status in adult diffuse gliomas Crsitina Alina Birzu (Paris, FR)
17:27 – 17:33	Genomic landscape of medulloblastoma in adults Tobias Goschzik (Bonn, DE)

\$`\$ \$`\$ \$`\$

17:45 – 19:15 Poster Viewing with Wine & Cheese

Topics:

P01 Liquid Biomarkers

- P02 Spinal tumors
- PO3 Patient-reported outcomes
- PO4 Low grade glioma
- P05 Early clinical trials
- P06 DIPG
- P07 Metabolic pathways
- P08 QoL/QoD
- P09 Meningeoma
- P10 Neuroimmunology
- P11 Preclinical neuro-oncology
- P12 Immunotherapy

19:30 – 23:30 Youngsters Networking Event Marriott Cité Internationale

Join the EANO Youngsters Networking Event and socialise with other young scientist and enjoy a nice evening with drinks and food. *The attendance is limited to PhD students. Tickets will be sold on first-come-first-served basis. See page 37 for further details.*







SATURDAY, SEPTEMBER 21

Saturday, September 21

08:00 – 09:00	Wake-Up Session 1: PCNSL Room: Amphithéâtre
	Chair: Uwe Schlegel (Bochum, DE), Jacoline Bromberg (Rotterdam, NL)
08:00 - 08:20	Evidence-based treatment of PCNSL – where do we stand? Jacoline Bromberg (Rotterdam, NL)
08:20 - 08:40	Management of PCNSL in the elderly Khe Hoang Xuan (Paris, FR)
08:40 - 09:00	Role of targeted therapies in PCNSL Lakshmi Nayak (Boston, US)
08:00 – 09:00	Wake-Up Session 2: EANM-EANO – Session – PET Imaging Room: Bellecour
	Chairs: Jörg Tonn (Munich, DE), Ian Law (Copenhagen, DK)
08:00 – 08:20	PET imaging of brain metastases Norbert Galldiks (Cologne, DE)
08:20 – 08:40	PET imaging in meningiomas Ian Law (Copenhagen, DK)
08:40 – 09:00	PET imaging for decision making in brain tumor surgery <i>Niklas Thon (Munich, DE)</i>
08:00 – 09:00	Wake-Up Session 3: Microenvironment Room: Gratte-Ciel
~~~~~~~~~~	Chairs: Pim French (Rotterdam, NL), Marc Sanson (Paris, FR)
08:00 – 08:20	Glioma-associated macrophages – friend or foe? Leila Akkari (Amsterdam, NL)
08:20 – 08:40	<b>Cellular and functional heterogeneity within the brain metastasis microenvironment</b> <i>Manuel Valiente (Madrid, ES)</i>
08:40 – 09:00	Microenvironmental heterogeneity in glioblastoma Antonio Iavarone (New York, US)
09:10 – 10:30	Joint EAN-EANO symposium on neuroimmunology Room: Amphithéâtre
	Chairs: Jérôme Honnorat (Lyon, FR) (EANO), Riccardo Soffietti (Turin, IT) (EAN)
09:10 – 09:35	Paraneoplastic syndromes Francesc Graus (Barcelona, ES)
09:35 – 09:55	Neurological complications of cancer Jérôme Honnorat, (Lyon, FR)
09:55 – 10:03	Specific genetic alterations of breast tumors lead to Yo paraneoplastic cerebellar syndromes Virginie Desestret (Lyon, FR)
10:03 - 10:11	Increased frequency of paraneoplastic encephalitis with anti-Ma2 antibodies in the cancer immunotherapy era <i>Alberto Vogrig (Lyon, FR)</i>
10:11 - 10:19	Autoimmune encephalitis as immune related adverse event (irAE) of check point inhibitors (CPI) not so rare as we thought. <i>Alisa Taliansky (Ramat-Gan, IL)</i>
10:19 - 10:27	Neurological follow-up of neurotoxicity after CAR T cell therapy in lymphoma patients: A French neurological multi-center survey. <i>Catherine Belin (Paris, FR)</i>

### **#\ #\ #**

### SATURDAY, SEPTEMBER 21

09:10 – 10:30	Pro-Con Session 1: Controversies in imaging and radiotherapy Room: Bellecour
	Chairs: Elizabeth Cohen-Jonathan-Moyal (Toulouse, FR), Marilena Theodorou (Nicosia, CY)
	Protons are standard of care
09:10 - 09:20	Pro: Damien Weber (Zurich, CH)
09:20 - 09:30	Con: Stephanie Combs (Munich, DE)
09:30 - 09:50	Discussion
	RANO/iRANO is sufficient for determining pseudoprogression
09:50 - 10:00	Pro: Olivier Chinot (Marseille, FR)
10:00 - 10:10	Con: Wolfgang Wick (Heidelberg, DE)
10:10 - 10:30	Discussion
09:10 - 10:30	Pro-Con Session 2: Controversies in molecular markers Room: Gratte-Ciel
	Chairs: Michael Weller (Zurich, CH), Lakshmi Nayak (Boston, US)
	MGMT-based treatment decisions
09:10 - 09:20	Pro: Tobias Kessler (Heidelberg, DE)
09:20 - 09:30	Con: Ulrich Herrlinger (Bonn, DE)
09:30 - 09:50	Discussion
	Targeted treatment decisions in recurrent glioblastoma
09:50 - 10:00	Pro: Colin Watts (Birmingham, UK)
10:00 - 10:10	Con: Antonella Castellano (Milan, IT)
10:10 - 10:30	Discussion
10:30 - 11:00	Coffee break
11:00 – 12:30	Oral Session 10: Highlights from clinical abstracts Room: Amphithéâtre
	Chairs: Amelie Darlix (Montpellier, FR), Tracy Batchelor (Boston, US)
11:00 - 11:15	Survival analysis of IDH wildtype astrocytomas with molecular features of glioblastoma, WHO grade IV Corneliu Tesileanu (Rotterdam, NL)
11:15 – 11:30	Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor- related epilepsy: results from a prospective, non-interventional study in European clinical practice <i>Roberta Rudà (Turin, IT)</i>
11:30 – 11:45	Primary therapy and survival in over 70-year-old patients with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands <i>Matthijs van der Meulen (Rotterdam, NL)</i>
11:45 – 12:00	Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for leptomeningeal metastasis from breast cancer - a randomized study. Final results <i>Emilie Le Rhun (Lille, FR)</i>
12:00 – 12:15	Outcome of unresectable de novo IDH wild-type GBM: A decade analysis of factors influencing survival. Alhafidz Hamdan (Glasgow, UK)
12:15 – 12:30	Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study <i>Adrew Lassman (New York, US)</i>

### SATURDAY, SEPTEMBER 21

11:00 – 12:30	Oral Session 11: EANO / SNO Session Room: Bellecour
	Chairs: Susan Chang, (San Francisco, US), Martin van den Bent (Rotterdam, NL)
11:00 - 11:15	New insights into signaling pathways in leptomeningeal metastasis Adrienne Boire (New York, US)
11:15 – 11:30	Vaccines for gliomas Michael Platten (Mannheim, DE)
11:30 - 11:45	Modelling glioma Simone Niclou (Luxembourg, LU)
11:45 - 12:00	<b>Novel aspects of IDH1 as a therapeutic target</b> <i>Gelareh Zadeh (Toronto, CA)</i>
12:00 - 12:15	<b>Obtaining evidence for targeted treatment in glioblastoma subgroups</b> <i>Wolfgang Wick (Heidelberg, DE)</i>
12:15 – 12:30	Imaging in Immunooncology – beyond iRANO Patrick Wen (Boston, US)
11:00 - 12:30	Oral Session 12: Highlights from preclinical abstracts Room: Gratte-Ciel
11:00 - 11:15	<i>Chairs: Anna Berghoff (Vienna, AT), Rolf Bjerkvig (Bergen, NO)</i> Editing of IDH1 R132H mutation in human induced pluripotent stem cells to investigate tumor genesis in glioma <i>Alexander Köpp (Dresden, DE)</i>
11:15 – 11:30	Targeting epigenetic pathways in the treatment of recurrent high-grade glioma Ann-Christin Hau (Luxembourg, LU)
11:30 - 11:45	L3MBTL3 is a novel suppressor of medulloblastoma tumorigenesis. Jean-Francois Rual (Ann Arbor, US)
11:45 - 12:00	In vivo dynamics and targeting of vessel co-option in glioma Giorgio Seano (Orsay, FR)
12:00 - 12:15	Small GTPase RHOE/RND3, a new critical regulator of NF-êB signaling in glioblastoma multiforme? Baohui Liu (Wuhan, CN)
12:15 – 12:30	Intracranial GBM PDX Mutations Induced by Temozolomide Treatment Charles David James (Chicago, US)
12:30 - 14:00	Lunch break
	Corporate Lunch Symposium
	For details see page 31
13:00 - 14:00	Workshop 3: Preclinical Models Room: Tête d'Or 2
	Chairs: Tobias Weiss (Zurich, CH), Anna Golebiewska (Luxembourg, LU)
	Pre-registration required, no fee. Please come to the registration desk to see if seats are still available. In case you booked this workshop, there is a mark with the workshop number on your badge.
13:00 - 13:05	Simone Niclou (Luxembourg, LU)
13:05 – 13:10	Heiko Wurdak (Leeds, UK)
13:10 - 13:15	Tobias Weiss (Zurich, CH)
13:15 - 13:55	Discussion
13:55 - 14:00	Summary

### *\$***6** *\$***6** *\$***6**

### SATURDAY, SEPTEMBER 21

13:00 – 14:00	Workshop 4: Clinical trial design Room: Tête d'Or Lounge Chairs: Marjolein Geurts (Utrecht, NL), Antoine Carpentier (Paris, FR) Pre-registration required, no fee. Please come to the registration desk to see if seats are still available. In case you booked this workshop, there is a mark with the workshop number on your badge.
13:00 - 13:05	Antoine Carpentier (Paris, FR)
13:05 - 13:10	Sabine Müller (San Francisco, US)
13:10 - 13:15	Martin van den Bent (Rotterdam, NL)
13:15 - 13:55	Discussion
13:55 – 14:00	Summary
14:05 – 15:35	Plenary Session 2: Immunotherapy Room: Amphithéâtre
	Chairs: Anna Berghoff (Vienna, AT), Patrick Roth (Zurich, CH)
14:05 – 14:35	Modulating the vascular immune axis to improve glioma therapy Gabriele Bergers (Leuven, BE)
14:35 - 15:05	<b>Target antigens in gliomas</b> Wolfgang Wick (Heidelberg, DE)
15:05 - 15:15	Exploiting the DNAM-1 system for chimeric antigen receptor (CAR) T cell therapy of glioblastoma <i>Tobias Weiss (Zurich, CH)</i>
15:15 – 15:25	Pembrolizumab (PEM) in recurrent high-grade glioma (HGG)patients with mismatch repair deficiency (dMMR): an observational study <i>Guiseppe Lombardi (Padova, IT)</i>
15:25 – 15:30	Discussion led by: Valerie Dutoit (Geneva, CH)
15:30 - 15:35	Q&A
15:45 – 17:15	Poster Viewing with Wine & Cheese
	Topics:
	P13 Omics in neuro-oncology
	P14 Clinical neuro-oncology
17:15 – 18:00	Corporate Symposium For details see page 31

#### 18:15 – 23:00 EANO XIV Evening

Enjoy a wonderful evening with a seated dinner with your colleagues and friends. *Please note that seats are limited, and tickets can only be bought in advance. Boarding is near the conference venue. See page 37 for further details.* 

### SUNDAY, SEPTEMBER 22

### Sunday, September 22

08:30 – 09:30	EANO Youngsters Session Room: Amphithéâtre
	Chairs: Matthias Preusser (Vienna, AT), Alessia Pellerino (Torino, IT)
08:30 - 08:45	How to write a successful paper Matthias Preusser (Vienna, AT)
08:45 - 09:00	<b>Dos and Don'ts in basic science – how to make your basic science project count</b> <i>Michael Platten (Mannheim, DE)</i>
09:00 - 09:15	What to expect and not to except from your PostDoc time Georg Widhalm (Vienna, AT)
09:15 – 09:30	Why Neuro-Oncology has a great work life balance Jacoline Bromberg (Rotterdam, NL)
09:30 - 10:30	General Assembly
10:30 - 11:00	Coffee break
11:00 - 11:30	Progress in neuro-oncology 2019: strategy of the EORTC Brain Tumor Group Room: Amphithéâtre Michael Weller (Zurich, CH)
11:30 - 12:30	Plenary Session 3: Hot Topics / Late Breaking Abstracts
11.50 - 12.50	Room: Amphithéâtre
	Chairs: Roberta Rudà (Turin, IT), Matthias Preusser (Vienna, AT)
11:30 - 11:40	A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1 <i>Ingo Mellinghoff (New York, US)</i>
11:40 - 11:50	Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) <i>Matthias Preusser (Vienna, AT</i> )
11:50 - 12:00	Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion <i>Corneliu Tesileanu (Rotterdam, NL)</i>
12:00 - 12:10	Intrinsic tumor plasticity in Glioblastoma allows for recreation of stem like-states and efficient tumor cell adaptation to new microenvironments <i>Anna Golebiewska (Luxembourg, LU)</i>
12:10 - 12:20	This presenter will receive the award for the best abstract in "Pre-clinical sciences" during the session.
12:10 - 12:20	Efficacy and safety of selinexor in recurrent glioblastoma Andrew Lassman (New York, US)
12:20 - 12:30	Targeting GSK-3 activity promotes mitotic catastrophe via centrosome destabilisation and enhances the effect of radiotherapy in glioma models <i>Susan Short (Leeds, UK)</i>
12:30 - 12:45	Closing remarks

### **SIDE MEETINGS**

### ALL SIDE MEETINGS ARE CLOSED MEETINGS.

As per date of printing.

### Thursday, September 19

07:00 - 08:00	RANO collaborative outcomes working group update and planning meeting	Tête d'Or 2
13:00 - 14:00	EORTC-1608: F2F meeting Adastra & EORTC	Tete d'Or 2
14:30 - 15:30	WFNOS website editorial board meeting	Tete d'Or 2
15:30 - 17:00	EANO future venues meeting	Tête d'Or 2
17:15 - 18:15	EORTC-BTC translational research committee meeting	Tête d'Or 1
17:15 - 18:15	EORTC meningioma committee meeting	Tête d'Or Lounge
17:30 - 18:30	1709 investigator meeting	Tête d'Or 2
Friday, Septen	nber 20	
09:30 - 11:00	EORTC 1608 investigator meeting	Tête d'Or 2
11:00 - 11:30	EANO guideline committee meeting	Tête d'Or 2
12:00 - 13:00	EORTC 1419 meeting	Tête d'Or 2
15:00 - 16:00	WFNOS general assembly	Tête d'Or 2
16:00 - 17:00	EANO national societies meeting	Tête d'Or 2
17:45 – 18:30	Meet the sponsors meeting	Tête d'Or 2
Saturday, Sept	tember 21	
09:00 - 10:30	EANO palliative care task force group meeting	Tête d'Or Lounge
10:00 - 12:00	BMS meeting	Tête d'Or 2
12:00 - 13:00	EANO educational committee meeting	Tête d'Or Lounge
15:30 - 16:30	Euracan instead of Eurocan	Tête d'Or 2
15:45 - 16:15	EORTC-1320: F2F meeting	Tête d'Or Lounge









# SCIENTIFIC INFORMATION



Oral Presentations													.26
Poster Presentation	S												.28

### 46 46 46

### **ORAL PRESENTATIONS**

#### PRESENTATIONS UPLOAD

All presentations need to be uploaded at least 2 hours before the session starts (30 minutes for the morning sessions).

The <u>preview centre</u> is located in the **Foyer Tête d'Or Parc on Level 1**, in the connector between the Amphithéâtre and the Tête d'Or rooms.

#### **PROJECTION AND TECHNICAL SETTING**

PowerPoint is the only communication tool available in all session halls.

The <u>preview centre</u> is located in the **Foyer Tête d'Or Parc on Level 1**, in the connector between the Amphithéâtre and the Tête d'Or rooms.

- 1. Speakers are kindly asked to observe that only computers provided by the congress may be used for showing your presentations. **All PowerPoint presentations must be handed in at the preview centre.**
- 2. All presentations are loaded into a PowerPoint handling system that will store and distribute your presentation to the session hall in time for your session.
- 3. All PowerPoint presentations should be handed in **at least 2 hours before the session starts**.

The opening hours of the pre-	view room are as ronows:
Wed, September 18	16:00 - 18:30
Thu, September 19	07:30 - 18:00
Fri, September 20	07:30 - 18:00
Sat, September 21	07:30 - 17:30
Sun, September 22	08:00 - 11:30
	00.00 11.00

- 4. Please check your presentation carefully on the preview room computer assigned by the staff before the final sign off.
- 5. The professional staff of the preview centre will load your presentation into the system so that it will be available on the computer in your session hall when you come to speak.
- 6. If you are doing more than one speech during the congress, you may upload all your presentations at the same time and they will be sent to their corresponding session halls at the time of your sessions.
- 7. The PowerPoint handling and distribution system is optimized for **MS PowerPoint (last version) and "*.pdf" (Adobe Acrobat)-files**. The uploading of "DVD-Movies" is not supported.
- The supported data media are: CD, DVD (as Data-storage-medium) and USB-Memory Key. You may want to carry a second key/CD as a back-up in case there is any insoluble technical problem.
   All needed files (including the movie files!) - have to be saved on the data media. Presentations can also be taken off speakers notebooks at the Preview centre.
- 9. The fonts that are used in the presentations should be "Latin-based fonts". If the speaker needs special fonts, they should be stored as "embedded fonts" with the presentation (File -> save as "name of presentation" and under "tools" -> save options mark the checkbox "embed True type fonts" and select "embed all characters").
- 10. When using mathematical symbols please use these which are available under Latin fonts (unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.
- As format for embedded movies "MPEG2 movies" are preferred (but can also be *.avi, *.wmv ). If Codecs are used, the Code package DIVx in the current version, which can be found under www.divx.com, should be chosen.
- 12. Presentations should be saved as "*.ppt", "*.pptx" (= PowerPoint) or "*.pps", *.ppsx" (=PowerPoint Slideshow)
   file and movies as separate files on the data media.
- 13. The computers and projectors will be set up and optimised for 1920 x 1080 resolution (ratio 16 : 9).

These guidelines should be seen as a matter of improving the effectiveness of the preview system and in consequence also the speakers' comfort.



### **ORAL PRESENTATIONS**

#### **PUBLICATION**

Please note that your work will be published in the September digital issue of the journal "NeuroOncology".

#### **SPEAKING TIME**

The chairpersons of your session will be strict in allowing no more than the time allotted to your paper. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

Please rehearse your talk to make sure it will fit comfortably into the available time.

Please note that, as a rule, presenters can show a (final) slide with all **acknowledgements**, however, in view of the short time available, **names cannot be read to the audience**.

Please see the detailed programme for any time changes.

#### COMMERCIAL DISCLOSURE INFORMATION

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide.

A **conflict of interest** is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.

If you have nothing to disclose, please state "I have no commercial disclosure".

# EANO 2019 CONGRESS APP

Everything important at a glance!

14th EANO Meeting 2019 European Association of Neuro-Oncology

Scan **QR-Code:** 



Or search for **medwhizz** in the App Store:





meduhizz[®] my congress companion

EANO Meeting Organiser Wiener Medizinische Akademie GmbH

### **POSTER PRESENTATIONS**

#### **POSTER VIEWING WITH AUTHORS**

Poster Session I Friday, September 20, 17:45-19:15							
Poster T	opics P01 – P12						
P01	Liquid biomarker P01.01-P01.02						
P02	Spinal tumors						
P03	Patient-reported outcomes						
P04	Low grade glioma						
P05	Early clinical trials						
P06	DIPG P06.01-P06.02						
P07	Metabolic pathways P07.01-P07.02						
P08	QoL/QoD P08.01-P08.06						
P09	Meningeoma P09.01-P09.08						
P10	Neuroimmunology						
P11	Preclinical neuro-oncology						
P12	Immunotherapy P12.01-P12.10						
Poster Session II Saturday, September 21, 15:45-17:15							
Poster Topics P13 – P14							
P13	Omics in neuro-oncology						
P14	Clinical neuro-oncology P14.01-P14.129						

### **POSTER PRESENTATIONS**

#### **INFORMATION FOR POSTER PRESENTERS**

#### **Poster Board Number**

Poster authors should have received their poster board number by email. You can also find your poster board on the website. Please note that both poster numbers for both days will be shown on the poster board. First poster number is indicated for the poster on Friday, Poster Session I, and the second poster number is indicated for the poster on Saturday, Poster Session II.

#### Poster Format

The usable surface on the poster board is **90 cm width x 150 cm height** and posters should be in **portrait format**. Only adhesive tape can be used to mount posters. Material to mount the posters is provided.

#### Schedule for display, mounting and removal

#### Friday, September 20, 17:45-19:15

#### Poster Session I (Poster Topics P01 - P12)

Poster mounting: For those posters displayed in poster session I the poster mounting is possible on Friday, September 20, from 07:30-10:00 hrs. Please make sure your poster is mounted until that time. Posters within the poster session I will be on display on Friday, September 20 from 17:45-19:15 hrs. Poster removal: Friday, September 20 from 19:15-19:30 hrs.

Please note that posters not removed until September 20, 19:30 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

#### Saturday, September 21, 15:45-17:15

#### Poster Session II (Poster Topics P13 – P14)

Poster mounting: For those posters displayed in poster session II the poster mounting is possible on Saturday, September 21, from 07:30-10:00 hrs. Please make sure your poster is mounted until that time. Posters within the poster session II will be on display on Saturday, September 21 from 15:45-17:15 hrs. Poster removal: Poster removal: Saturday, September 21 from 17:15-17:30 hrs.

### Please note that posters not removed until September 21, 17:30 hrs, will be taken down and will not be stored or sent to the authors after the meeting.

#### **Presence at Posters**

Please note that the posters have been divided into two separate poster sessions. In order to enable discussion and interaction with other participants, it is mandatory for you or one of your group members to be present at your poster board during the according poster session.

# ean Paris congress 2020

6th Congress of the European Academy of Neurology May 23 – 26



Abstract submission deadline 08 January 2020 Early registration deadline 16 March 2020

# Time for Action Predict. Prevent. Repair.



www.ean.org/paris2020 #ean2020 🎔 f 💿

## CORPORATE SYMPOSIA



### **\$6 \$6 \$6**

### **CORPORATE SYMPOSIA**

#### Corporate Lunch Symposium 1 – CarThera

#### Overcoming Barriers: Ultrasound and the BBB

Date: Friday, September 20 Time: 13:05 – 14:20 hrs Room: Bellecour



#### Chairs: Jean-Yves Delattre (Paris, FR), Roger Stupp (Chicago, US)

13:05 – 13:10	Introduction Jean-Yves Delattre (Paris, FR)
13:10 – 13:25	Efficiently tailoring local brain tumor therapy - challenges and surgical perspectives <i>Jörg Tonn (Munich, DE)</i>
13:25 – 13:40	Ultrasound based BBB Opening and results of phase 1 trial <i>Alexandre Carpentier (Paris, FR)</i>
13:40 – 13:55	Overcoming challenges in treating brain tumors John De Groot (Houston, US)
13:55 – 14:10	Summary review & perspectives Roger Stupp (Chicago, US)

14:10 – 14:20 Q&A to speakers and Ahmed Idbaih (Paris, FR), principal investigator

#### Corporate Lunch Workshop 1 – Illumina

#### DNA Methylation Profiling as a tool for Classifying Brain Tumors

Date: Friday, September 20 Time: 13:05 – 14:20 hrs Room: Tête d'Or 1

# illumina

13:05 – 13:15	Welcome Aida Soler (Madrid, ES) - Sr Segment Marketing Manager – Cancer Research, Illumina
13:15 – 14:05	DNA Methylation Profiling as a tool for Classifying Brain Tumors Felix Sahm (Heidelberg, DE)
14:05 - 14:20	Question and Answers

### **CORPORATE SYMPOSIA**

abbvie

#### Corporate Lunch Symposium 2 – AbbVie, Inc.

Biomarkers and Therapies in GBM - What we have learned and what is new

Date: Saturday, September 21 Time: 12:45 – 14:00 hrs Room: Bellecour

Chairs: Andreas von Deimling (Heidelberg, DE), Marc Sanson (Paris, FR), Martin van den Bent (Rotterdam, NL)

- 13:00 13:05 Welcome and introduction Marc Sanson (Paris, FR)
  13:05 – 13:25 Biomarkers in GBM
- Andreas von Deimling (Heidelberg, DE)
- 13:25 13:45 Therapies for GBM: Lessons learned and new developments *Martin van den Bent (Rotterdam, NL)*
- 13:45 14:00 Panel Discussion

#### Corporate Symposium 3 – Bristol-Myers Squibb

New Horizons for Immuno-Oncology and MGMT methylation in Glioblastoma

Date: Saturday, September 21 Time: 17:15 – 18:00 hrs Room: Bellecour Bristol-Myers Squibb

Chairs: Michael Lim (Baltimore, US), Michael Weller (Zurich, CH)

17:15 - 17:25 Understanding of glioblastoma biology and MGMT promoter methylation as a biomarker - implications for management *Michael Weller (Zurich, CH)* 17:25 - 17:45 Emerging findings in glioblastoma biology - strategies to overcome the immunosuppressive environment

Michael Lim (Baltimore, US)

- 17:45 17:55 Immuno-oncology for treatment of GBM current state and novel approaches *Michael Weller (Zurich, CH)*
- 17:55 18:00 Q&A



We're driving our research toward the future of **PRECISION MEDICINE.** 



© 2019 Bristol-Myers Squibb Company. All rights reserved. IOFR1900790-01 - NP - August 2019



# INFORMATION



Networking Events
General Information
Registration
Sponsors
Exhibitors

# **#**``#``#``

# **NETWORKING EVENTS**

# **Networking Event**

Lyon City Hall - Hôtel de Ville Thursday, September 19, 2019 Start: 19:00 hrs

Address: 1 Place de la Comédie, 69001 Lyon, France

Spend a nice evening with your colleagues while enjoying finger food and drinks.

*Please note that advance registration is mandatory in order to receive a ticket! Limited attendance!* 

For regular participants:	included in the registration fee
Extra ticket:	EUR 48,- (incl. VAT)
Dress code:	casual

Participation is included in the registration fee but registration for the event is necessary in advance.

Please note that no transportation will be provided by the conference organiser and you will need to make your own way to the evening venue. No sponsoring is used to fund any part of the evening.





# **NETWORKING EVENTS**

# **Youngsters Networking Event**

Marriott Cité Internationale Friday, September 20, 2019 Start: 19:30 hrs

Address: 70 Quai Charles de Gaulle, 69463 Lyon, France

Join the EANO Youngsters Networking Event and socialise with other young scientist and enjoy a nice evening with drinks and food.

Ticket:EURDress code:casua

EUR 10,- (incl. VAT) casual

The attendance is limited! Tickets will be sold on first-come-first-served basis.



© www.marriott.com/hotels/travel/lysmc-lyon-marriott-hotel-cite-internationale/

# **EANO XIV Evening**

Dinner cruise on Hermès Boat Saturday, September 21, 2019 Boarding: 18:15-18:45hrs (strict!)

Enjoy a wonderful evening with a seated dinner with your colleagues and friends.

Please note that seats are limited, and advance registration is mandatory in order to receive a ticket!

**Regular participants / extra ticket: Nurse / AHP / PhD Student / Resident / Trainee*:** **only applicable with adequate fee.*  EUR 95,- (incl. VAT) per person EUR 50,- (incl. VAT) per person

Dress code: formal



No sponsoring is used to fund any part of the evening. Boarding: Promenade du Bas Rhône at the pier next to the Passerelle de la Paix bridge on the Rhone river

Disembarkation: 16 Quai Claude Bernard, nearby La Place Bellecour (in the city centre).

Individual return to your hotel.

© www.lesbateauxlyonnais.com

# IT'S TIME TO PAINT A BETTER PICTURE OF HIGH GRADE GLIOMA

Learn more about the current treatment landscape in high grade glioma, and why another approach is needed.

Visit FUTUREofGLIOMA.com to learn more.



©2019 Tocagen. All rights reserved. VV-REG-002970 07/19



# **GENERAL INFORMATION**

### BADGES

Participants should collect their name badge from the conference registration desk. Since only registered participants will be permitted to attend the scientific sessions, the exhibition and poster areas, you are kindly asked to wear your badge when entering the congress venue.

Lost badges can be replaced at the registration desk. However, a handling fee of EURO 55.- incl. VAT will be charged.

### **CAR PARKING**

There are 3 carparks at the venue:

- P0 1.000 parking spaces, maximum vehicle height: 1.90 m
- P1 1.150 parking spaces, maximum vehicle height: 1.90 m
- P2 1.200 places, parking spaces, maximum vehicle height: 2.70 m

### CME CERTIFICATE/CONFIRMATION OF ATTENDANCE

Confirmations of attendance and payment will be issued electronically via email after the conference to all participants. Participants interested in obtaining CME credits need to get their name badges scanned **daily** at the Registration Desk and will be able to download their CME Certificate after completion of the post-congress survey. Please note that if you miss to scan your badge you will not receive the credits accredited for that day.

### **CLOAKROOM AND LUGGAGE**

A cloakroom and luggage storage facilities are available in the congress venue on Level -1, next to the registration. Please be aware of the security measures in place and arrive timely in the morning, especially with luggage.

### **CME CREDITS**

The **14th Meeting of the European Association of Neuro-Oncology, Lyon, France, September 19-22, 2019** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME[®]) with **24** European CME credits (ECMEC[®]s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Further details can be found on page 4.

### **COFFEE BREAKS**

During the morning session breaks, refreshments (coffee, tea and pastries) will be served free of charge to participants wearing name badges in the exhibition area.

### DRINKING WATER

The tap water in Lyon can be used without concern.

### **EXHIBITION OPENING HOURS**

Thursday, September 19, 2019 Friday, September 20, 2019 Saturday, September 21, 2019 09:00 - 17:00 hrs 09:00 - 19:15 hrs 09:00 - 17:15 hrs

### **INSURANCE**

In registering for the EANO 2019 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance.

# **GENERAL INFORMATION**

# INTERNET

Internet stations will be available in the exhibition area. WIFI is available in all areas. The access codes are: Network: EANO2019 Password: eano2019

# LANGUAGE

The official language of the congress will be English (no simultaneous translation).

# LUNCH AND REFRESHMENTS

During the lunch breaks, a **light lunch** will be offered free of charge to participants wearing name badges.

### **PREVIEW ROOM**

The <u>preview centre</u> is located in the Foyer Tête d'Or Parc on Level 1, in the connector between the Amphithéâtre and the Tête d'Or rooms.

# **PROGRAMME CHANGES – ACCESS TO SESSIONS**

The conference organisers reserve a right to modify the programme and cannot assume any liability for changes in the programme due to external or unforeseen circumstances. No refunds can be granted in case of cancellation of speakers, lack of space in the conference room or any other incidents during the conference which are beyond the control of the conference organiser.

<b>REGISTRATION DESK OPENING HOURS</b>	
Wednesday, September 18	16:00 - 18:30 hrs
Thursday, September 19	07:30 – 18:00 hrs
Friday, September 20	07:30 – 18:00 hrs
Saturday, September 21	07:30 – 17:30 hrs
Sunday, September 22	08:15 – 11:30 hrs

# **SMOKING POLICY**

The EANO 2019 is officially a "No-smoking-Conference". Note that smoking is banned in public buildings, restaurants and bars.

# STAFF

In case of any questions, the conference staff - recognizable by a neon yellow lanyard - will be pleased to help you.

# V.A.T.

The standard V.A.T. rate in France is 20%. All registration fees are stated in EUR including VAT.

# VENUE

# Centre de Congrès – CITÉ

50 Quai Charles de Gaulle | 69463 Lyon Cedex 06, France T: +33 4 72 82 26 26 | www.ccc-lyon.com



# **GENERAL INFORMATION**

### LYON ACCESSIBILITY

Lyon has an extensive public transport network (known as 'TCL', with metro lines, tramways, buses and funicular trains), which makes it easy and quick to get from one part of the city to another. There are different types of tickets available to suit various needs. You can find information about ticket prices and maps of the public transport network on the TCL website.

### TO AND FROM THE AIRPORT

Lyon Saint Exupéry airport, France's 2nd regional airport, serves 117 destinations of which 80 are international with more than forty airlines. An additional business airport – Lyon Bron is just 20 minutes outside the city centre. www.lyonaeroports.com/en/

### Train:

The airport Lyon Saint Exupéry is directly connected to the TGV and to the city every 15 minutes in under 30 minutes thanks to the Rhone Express rail line. Departures everyday between 4:25 hrs to midight, all year long. You can buy your tickets here: https://store.lyonaeroports.com/acces-transports/rhonexpress.

The price for a one way ticket is  $15,20 \in$  and the price for a round trip is  $26,70 \in$ .

### Taxi:

Taxifares to the congress venue take around 30-40 minutes. There is a taxi rank directly outside terminals 1, 2 and the train station. Always ask the driver before you start your trip about what price is in effect. If you want to book an airport transfer in advance: www.airportaxi.fr (website only in French)

## ACCESS TO THE CONFERENCE VENUE

### By Train

The Lyon Convention centre is 10 just minutes from the Lyon Part-Dieu TGV station and only 15 minutes from the Perrache train station. Between Lyon and Paris, there is one TGV per hour, or even every half hour. https://en.oui.sncf/en/

### By Bus

Take the C1 bus from Gare Part Dieu train Station - stop at Cité internationale | Centre de Congrès. Take the C2 bus from Gare Part Dieu train Station – stop at Cité internationale | Transbordeur

Take the C4 bus from the Jean Macé metro station or Foch-Roosevelt metro station - stop at Cité internationale | Congress Center Take the C5 bus from the Cordeliers metro station – stop at Cité internationale | Congress Center

Take the C26 bus from Grange Blanche metro station – stop at Cité internationale I Transbordeur

Take number 70 bus from Lyon Part Dieu train station – stop at Cité internationale l Transbordeur Plan your itinerary here: www.tcl.fr/en

### By Taxi

There are 2 dedicated taxi pick up zones in front of the Lyon Convention Centre.

- Zone 1: Close to the main entrance at the foot of the bear statue
- Zone 2: Close to the main amphithéâtre

Taxi Radio is the leading reservation centre for Lyon's taxis: 400 drivers are on call whatever the time of day or night +34 472 10 86 86; www.taxilyon.com (website only in French).

AlloTaxi: +34 478 28 23 23; www.tl.fr/taxi-lyon/en-reserver-un-taxi-a-lyon.html

### By Car

Take the north-bound ring road (Peripherique Nord) and exit at Porte de Saint Clair. GPS coordinates: Latitude: 45.7851676 | Longitude: 4.8528885 Address: 50 quai Charles de Gaulle - 69006 Lyon - France

### By Bike

The convention centre district has 5 Velo'v stations onsite. One is conveniently located at the main entrance and the other is close to the Amphithéâtre. https://velov.grandlyon.com/home



**Elevate Expectations** 

EXPERIENCE > 12.000 GBM PATIENTS TREATED TO DATE GLOBALLY AVAILABILITY > 260 CERTIFIED MEDICAL CENTERS IN EUROPE

PUT GBM ON **PAUSE** 

# PUT LIFE ON **PLAY**



# OPTUNE[®] + TMZ HAS BEEN PROVEN TO **PROVIDE LONG - TERM QUALITY SURVIVAL** TO PATIENTS WITH NEWLY DIAGNOSED GBM^{1,2}

Survival with Optune +TMZ vs TMZ alone was significantly better at the 2- and 5-year landmark analyses¹



13% vs 5% Optune + TMZ TMZ alone

- Median OS was significantly extended with Optune + TMZ vs TMZ alone by nearly 5 month (P<0,001)¹
- Optune + TMZ also significantly improved PFS vs TMZ alone (median PFS: 6,7 month vs 4,0 month, P<0,001)¹

# Visit our booth to lern more

References: 1. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 2. Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):495-504.







# REGISTRATION

### REGISTRATION

# Onsite registration is possible during the opening hours of the registration desk as follows:

16:00 - 18:30 hrs
07:30 - 18:00 hrs
07:30 - 18:00 hrs
07:30 - 17:30 hrs
08:15 - 11:30 hrs

### **REGISTRATION FEES**

EANO MEETING: SEPTEMBER 20 - 22, 2019				
PAYMENT RECEIVED*	REDUCED RATE until June 25	REGULAR R from June 2 August 13		LATE & ON-SITE RATE after August 13
EANO Member (to join EANO click here)	EUR 485,-	EUR 570,-		EUR 645,-
Non Member	EUR 755,-	EUR 840,-		EUR 910,-
Nurse / AHP - EANO Member	EUR 170,-	EUR 170,-		EUR 225,-
Nurse / AHP - Non Member	EUR 260,-	EUR 260,-		EUR 320,-
PhD Student/ Resident/Trainee**	EUR 260,-	EUR 260,-		EUR 320,-
EDCUATIONAL DAYS: SEPTEMBER 19, 2019				
EANO-EORTC Educational Day	EUR 225,- EUR 240,- EUR 26		EUR 260,-	
Educational Day for Nurses <u>Nurses / AHPs</u> registered for the EANO meeting	EUR 0,- EUR 0,-			EUR 0,-
<b>Educational Day for Nurses</b> All other persons (EANO delegates & outsiders)	EUR 60,-	EUR 60,-		EUR 60,-
Networking Event	Included in the registration fee (ticket for addtitional person EUR 48,-)			
Youngsters Networking Event	EUR 10,-			
EANO XIV Evening	Regular participant PhD Student/Resid./Tra (ticket for addtional person) Nurse/AHP			
-	EUR 95,-			EUR 50,-

All prices include 20% VAT and are collected in EURO only.

* Please note that the day of payment is decisive for the registration fee, not the day of registration.

** PhD students, residents and trainees: Please provide a copy of a Student's ID or a confirmation signed by the head of department at the moment of your registration by email to eano-meetings@eano.eu. Confirmations handed in at a later stage cannot be considered.

### Please note:

Pre-registration without payment of the registration fee is possible. The onsite fee will then have to be paid at the registration desk (credit card or cash in EUR).

### What is included in the EANO Meeting fee?

- Admission to all scientific sessions
- Admission to exhibition
- Admission to EANO Networking Event (free of charge but registration is mandatory!)
- Final programme
- Coffee/tea during breaks
- Light lunch

# **\$6 \$6 \$6**

# REGISTRATION

# EANO Educational Day: September 19, 2019

The EANO Educational Course is done in collaboration with the EORTC and shares the format of the well perceived EANO/ESMO/EORTC training course. The course will be in English and will feature a series of well-known international experts in the field on all topics relevant for a detailed introduction to or update on Neuro-Oncology. The concept of the course allows all PhD students or residents to get a full insight into modern Neuro-Oncology.

# How to register for the Educational Day?

If you wish to attend the Educational Day, please note that it is **NOT** included in the registration fee of the EANO 2019 Meeting. The Educational Day is subject to additional registration and costs. In case you already registered for the EANO 2019 Meeting and have now decided to attend the Educational Day additionally, please contact the registration manager.

# **REGISTRATION FEES (EDUCATIONAL DAY EANO-EORTC)**

PAYMENT RECEIVED*	REDUCED RATE until June 25	REGULAR RATE from June 26 to August 13	LATE & ON-SITE RATE after August 13
EANO-EORTC Educational Day	EUR 225,-	EUR 240,-	EUR 260,-

All prices include 20% VAT and are collected in EURO only.

* Please note that the day of payment is decisive for the registration fee, not the day of registration.

# What is included in the Educational Day fee?

- Admission to courses of your choice
- Syllabus
- Coffee/tea during breaks
- Light lunch

# EANO 2019 CONGRESS APP

Everything important at a glance!


14th EANO Meeting 2019 European Association of Neuro-Oncology



Or search for **medwhizz** in the App Store:

Download on the App Store

meduhizz my congress companion





# REGISTRATION

# **4**6 **4**6 **4**6

# **PAYMENT MODALITIES**

Payment of Registration fees, may be made in EURO by:

- **Bank transfer** to the conference account (before the conference) Payments should be made without charges to the beneficiary. Any bank charges will be collected on site. Clearly state the participant's name(s), matching with the name(s) on the registration form.
- Credit Cards: Diners Club, Mastercard and Visa.
- **Cash** in EUR only.

### **IMPORTANT**

The reduced registration fee is only applicable, if it has been paid to the congress account within the according deadlines. Registering without performing an actual payment will automatically set your balance to the fee applicable onsite.

### PAYMENT DEADLINES

Reduced Rate:	until June 25, 2019
Regular Rate:	June 26 - August 13, 2019
Late & On-site Rate:	after August 13, 2019

# CANCELLATIONS AND REFUNDS

Notice of cancellation must be made in writing by email or fax to the Congress Office.

Registration fees may be refunded as follows:

٠	before June 25, 2019:	75% Refund
٠	June 26 - August 13, 2019:	25% Refund
٠	after August 13, 2019:	No Refund

The cancellation will not be effective until a written acknowledgement from the EANO 2019 Registration Department is received.

In the case of over-payment or double payment, refund requests must be made in writing and sent to the EANO 2019 Registration Department by email.

No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers, lack of space in the lecture room or any other incidents during the meeting, which are beyond the control of the meeting organisers.

No exceptions to the refund policy can be made, including health or family issues, however, we welcome substitute delegates at any time. By registering to the EANO 2019 participants agree that neither the organising committee nor the organising office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

# **st st**

# **SPONSORS**

The European Association of Neuro-Oncology gratefully acknowledges the support of the following institutions, companies and organisations (as per date of printing).

# **SPONSORS**

PLATINUM SPONSOR



# GOLD SPONSORS



# SILVER SPONSOR



# SPONSORS





# illumina

* neurodiem™ a service from Biogen



# **EXHIBITORS**



ACCURAY BRAINSTRUST EANO ELEKTA IBTA MEDAC NOVOCURE ORBUS THERAPEUTICS SOPHIA GENETICS TOCAGEN ZAP SURGICAL

**EXHIBITORS** 




www.eano.eu


**\$6 \$6 \$6** 

# **Tocagen** No One Should Die Of Cancer^M

Explore the latest potential therapeutic innovations for high grade glioma

# Come see us at Booth #6, and learn more about the Tocagen pipeline.

©2019 Tocagen. All rights reserved. VV-REG-002998 08/19


543	- <b>7</b>	


# Coordination

WMA GmbH EANO 2019 Alser Strasse 4 • 1090 Vienna • Austria t: +43 1 405 13 83 - 11 e: eano-meetings@eano.eu www.eano.eu

 Layout:
 Barbara Biegl, www.biegl-grafik.at

 Photo Credits:
 Unless otherwise indicated all pictures

 © EANO – European Association of Neuro-Oncology

Copyright © 2019 EANO

All rights reserved. No part of this publication may be reproduced, distributed or transmitted without the prior written permission of EANO. Content as per date of printing. Some information may be subject to change.

Join the discussion

Saturday 21 September Lyon, France

Bellecour Convention Center Level 1

# What We Have Learned and What is New

# AGENDA

in GBM

**Biomarkers** 

and Therapies

# 13:00-13:05

# Welcome and Introduction

Prof. Marc Sanson, MD PhD

# 13:05-13:25

# **Biomarkers in GBM**

Prof. Andreas von Deimling, MD

# 13:25-13:45

# Therapies for GBM: Lessons Learned and New Developments

Prof. Martin van den Bent, MD

# 13:45-14:00

# **Panel Discussion**

Chairman and Panel

# LUNCH will be provided

# FACULTY

# CHAIRMAN

Prof. Marc Sanson, MD PhD Professor, Sorbonne University, AP-HP Paris, France

# Prof. Andreas von Deimling, MD

Professor, Director of Neuropathology University Hospital Heidelberg, and, director of Clinical Cooperaion Unit Neuropathology, German Cancer Center (DKFZ)

Heidelberg, Germany

# Prof. Martin van den Bent, MD

Professor, Erasmus University Medical Center **Rotterdam, Netherlands** 

# REGISTER NOW using the EANO app

Supported by an education grant from AbbVie



# EANO 2020 GLASGOW

A PERMIT

SEPTEMBER 10 - 13, 2020 15TH MEETING & Educational Day EUROPEAN ASSOCIATION

SAVE THE DATE

OF NEURO-ONCOLOGY

Scottish Event Campus (SEC) Glasgow, United Kingdom



www.eano.eu

SAVE THE DATE

www.eano.eu